Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 12 HER2-positive Breast Cancer 6 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Salivary Gland Neoplasms 1 Rare Tumor 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-positive Advanced Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2 Positive Breast Cancer 1 HER2 Insertion Mutation Positive Advanced NSCLC 1 Esophageal Squamous Cell Carcinoma 1 Breast Neoplasm Female 1 Breast Cancer Metastatic 1 Breast Cancer Invasive 1 Breast Cancer Female 1 Advanced Breast Cancer 1

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Rare Tumor × pyrotinib × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡